Literature DB >> 14968797

Medicare program; changes to Medicare payment for drugs and physician fee schedule payments for calendar year 2004. Interim final rule with comment period.

.   

Abstract

This interim final rule implements the provisions of the Medicare Prescription Drug, Improvement, and Modernization Act (MPDIMA) of 2003, Pub. L. 108-173, which are applicable in 2004 to Medicare payment for covered drugs and physician fee schedule services. These provisions revise the current payment methodology for Part B covered drugs and biologicals that are not paid on a cost or prospective payment basis; make changes to Medicare payment for furnishing or administering drugs and biologicals; revise the geographic practice cost indices and change the physician fee schedule conversion factor. The 2004 physician fee schedule conversion factor will be $37.3374. The 2004 national anesthesia conversion factor (prior to making adjustment for the geographic practice cost indices) will be $17.4969. The information contained in this final rule related to payment under the physician fee schedule supercedes the information contained in the November 7, 2003, final rule to the extent that the two are inconsistent. All other provisions of the November 7, 2003, final rule are unchanged unless otherwise noted. This rule also extends the "opt-out" provisions of 1802(b)(5)(3) of the Social Security Act to dentists, podiatrists, and optometrists.

Mesh:

Year:  2004        PMID: 14968797

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  4 in total

1.  Reimbursement issues with hormonal therapies for prostate cancer.

Authors:  M Ray Painter
Journal:  Rev Urol       Date:  2005

2.  The changing face of urology in 2005.

Authors:  M Ray Painter
Journal:  Rev Urol       Date:  2004

3.  Costs and state-specific rates of thoracic and lumbar vertebroplasty, 2001-2005.

Authors:  Darryl T Gray; William Hollingworth; Nneka Onwudiwe; Jeffrey G Jarvik
Journal:  Spine (Phila Pa 1976)       Date:  2008-08-01       Impact factor: 3.468

Review 4.  Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.

Authors:  Shelby D Reed; Kevin J Anstrom; Yanhong Li; Kevin A Schulman
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.